Core Viewpoint - The oral semaglutide (Wegovy pill) has gained FDA approval, marking a significant turning point for Novo Nordisk A/S [1] Group 1: FDA Approval Impact - The approval of the oral semaglutide is seen as a pivotal moment for Novo Nordisk, potentially enhancing its market position [1] Group 2: Company Background - Novo Nordisk is recognized for its innovative approaches in the pharmaceutical industry, particularly in diabetes and obesity treatments [1]